Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System [PDF]
Journal of XenobioticsBackground: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj +2 more sources
Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system [PDF]
PLoS ONEBackgroundGlofitamab offers a promising option for the treatment of diffuse large B-cell lymphoma. It is crucial to gather comprehensive safety information of glofitamab through large-scale post market monitoring.MethodsThis study conducted a ...
Meng Zhou, Cheng Jiang, Chuanyong Su
doaj +3 more sources
Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System [PDF]
Frontiers in MedicineObjectiveTo mine adverse drug events (ADEs) following the use of gemtuzumab ozogamicin based on the FDA Adverse Event Reporting System (FAERS), and to provide references for the safety assessment of clinical drug use.MethodsWe obtained reports of adverse
Xuexue Liu +10 more
doaj +2 more sources
Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system [PDF]
BMC Pharmacology and ToxicologyBackground Cefotaxime has been widely used in the clinical treatment of infections. However, there is still a lack of systematic researches for the adverse event profiles of cefotaxime through large-scale post-marketing monitoring.
Cheng Jiang +3 more
doaj +2 more sources
Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS) [PDF]
Frontiers in PharmacologyObjectiveLaronidase is the first drug of enzyme replacement therapy approved for the treatment of mucopolysaccharidosis type I (MPS I). However, its adverse events (AEs) have not been investigated in real - world settings.
Zhuomiao Lin +4 more
doaj +2 more sources
Adverse event reporting of mirtazapine: A disproportionality analysis of FDA adverse event reporting system (FAERS) database from 2004-2024. [PDF]
PLoS ONEBackgroundMirtazapine is a pharmacological agent commonly utilized as a first-line treatment for major depressive disorder, exhibiting both noradrenergic and selective serotonergic activity.
Keying Guo +5 more
doaj +2 more sources
Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system [PDF]
Frontiers in PharmacologyBackgroundMaribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation.
Haolin Teng +3 more
doaj +2 more sources
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea [PDF]
Clinical and Experimental Pediatrics, 2023 As of June 2022, 5 coronavirus disease 2019 (COVID-19) vaccine brands have been used in Korea’s national immunization program. The Korea Disease Control and Prevention Agency has enhanced vaccine safety monitoring through a passive web-based reporting ...
Yeon-Kyeng Lee +10 more
doaj +1 more source
Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system [PDF]
Frontiers in NeurologyBackgroundAlzheimer’s disease (AD) has a growing global prevalence, and the need for safe and effective treatments is urgent. Donepezil is commonly used therapeutic agents for AD but has safety controversies. The objective of this study was to thoroughly
Shuo Li +16 more
doaj +2 more sources
COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021 [PDF]
Osong Public Health and Research Perspectives, 2021 Objectives On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and ...
Hyun-kyung Oh +6 more
doaj +1 more source